Journal of Clinical and Diagnostic Research, ISSN - 0973 - 709X

Users Online : 76181

AbstractConclusionReferencesDOI and Others
Article in PDF How to Cite Citation Manager Readers' Comments (0) Audio Visual Article Statistics Link to PUBMED Print this Article Send to a Friend
Advertisers Access Statistics Resources

Dr Mohan Z Mani

"Thank you very much for having published my article in record time.I would like to compliment you and your entire staff for your promptness, courtesy, and willingness to be customer friendly, which is quite unusual.I was given your reference by a colleague in pathology,and was able to directly phone your editorial office for clarifications.I would particularly like to thank the publication managers and the Assistant Editor who were following up my article. I would also like to thank you for adjusting the money I paid initially into payment for my modified article,and refunding the balance.
I wish all success to your journal and look forward to sending you any suitable similar article in future"



Dr Mohan Z Mani,
Professor & Head,
Department of Dermatolgy,
Believers Church Medical College,
Thiruvalla, Kerala
On Sep 2018




Prof. Somashekhar Nimbalkar

"Over the last few years, we have published our research regularly in Journal of Clinical and Diagnostic Research. Having published in more than 20 high impact journals over the last five years including several high impact ones and reviewing articles for even more journals across my fields of interest, we value our published work in JCDR for their high standards in publishing scientific articles. The ease of submission, the rapid reviews in under a month, the high quality of their reviewers and keen attention to the final process of proofs and publication, ensure that there are no mistakes in the final article. We have been asked clarifications on several occasions and have been happy to provide them and it exemplifies the commitment to quality of the team at JCDR."



Prof. Somashekhar Nimbalkar
Head, Department of Pediatrics, Pramukhswami Medical College, Karamsad
Chairman, Research Group, Charutar Arogya Mandal, Karamsad
National Joint Coordinator - Advanced IAP NNF NRP Program
Ex-Member, Governing Body, National Neonatology Forum, New Delhi
Ex-President - National Neonatology Forum Gujarat State Chapter
Department of Pediatrics, Pramukhswami Medical College, Karamsad, Anand, Gujarat.
On Sep 2018




Dr. Kalyani R

"Journal of Clinical and Diagnostic Research is at present a well-known Indian originated scientific journal which started with a humble beginning. I have been associated with this journal since many years. I appreciate the Editor, Dr. Hemant Jain, for his constant effort in bringing up this journal to the present status right from the scratch. The journal is multidisciplinary. It encourages in publishing the scientific articles from postgraduates and also the beginners who start their career. At the same time the journal also caters for the high quality articles from specialty and super-specialty researchers. Hence it provides a platform for the scientist and researchers to publish. The other aspect of it is, the readers get the information regarding the most recent developments in science which can be used for teaching, research, treating patients and to some extent take preventive measures against certain diseases. The journal is contributing immensely to the society at national and international level."



Dr Kalyani R
Professor and Head
Department of Pathology
Sri Devaraj Urs Medical College
Sri Devaraj Urs Academy of Higher Education and Research , Kolar, Karnataka
On Sep 2018




Dr. Saumya Navit

"As a peer-reviewed journal, the Journal of Clinical and Diagnostic Research provides an opportunity to researchers, scientists and budding professionals to explore the developments in the field of medicine and dentistry and their varied specialities, thus extending our view on biological diversities of living species in relation to medicine.
‘Knowledge is treasure of a wise man.’ The free access of this journal provides an immense scope of learning for the both the old and the young in field of medicine and dentistry as well. The multidisciplinary nature of the journal makes it a better platform to absorb all that is being researched and developed. The publication process is systematic and professional. Online submission, publication and peer reviewing makes it a user-friendly journal.
As an experienced dentist and an academician, I proudly recommend this journal to the dental fraternity as a good quality open access platform for rapid communication of their cutting-edge research progress and discovery.
I wish JCDR a great success and I hope that journal will soar higher with the passing time."



Dr Saumya Navit
Professor and Head
Department of Pediatric Dentistry
Saraswati Dental College
Lucknow
On Sep 2018




Dr. Arunava Biswas

"My sincere attachment with JCDR as an author as well as reviewer is a learning experience . Their systematic approach in publication of article in various categories is really praiseworthy.
Their prompt and timely response to review's query and the manner in which they have set the reviewing process helps in extracting the best possible scientific writings for publication.
It's a honour and pride to be a part of the JCDR team. My very best wishes to JCDR and hope it will sparkle up above the sky as a high indexed journal in near future."



Dr. Arunava Biswas
MD, DM (Clinical Pharmacology)
Assistant Professor
Department of Pharmacology
Calcutta National Medical College & Hospital , Kolkata




Dr. C.S. Ramesh Babu
" Journal of Clinical and Diagnostic Research (JCDR) is a multi-specialty medical and dental journal publishing high quality research articles in almost all branches of medicine. The quality of printing of figures and tables is excellent and comparable to any International journal. An added advantage is nominal publication charges and monthly issue of the journal and more chances of an article being accepted for publication. Moreover being a multi-specialty journal an article concerning a particular specialty has a wider reach of readers of other related specialties also. As an author and reviewer for several years I find this Journal most suitable and highly recommend this Journal."
Best regards,
C.S. Ramesh Babu,
Associate Professor of Anatomy,
Muzaffarnagar Medical College,
Muzaffarnagar.
On Aug 2018




Dr. Arundhathi. S
"Journal of Clinical and Diagnostic Research (JCDR) is a reputed peer reviewed journal and is constantly involved in publishing high quality research articles related to medicine. Its been a great pleasure to be associated with this esteemed journal as a reviewer and as an author for a couple of years. The editorial board consists of many dedicated and reputed experts as its members and they are doing an appreciable work in guiding budding researchers. JCDR is doing a commendable job in scientific research by promoting excellent quality research & review articles and case reports & series. The reviewers provide appropriate suggestions that improve the quality of articles. I strongly recommend my fraternity to encourage JCDR by contributing their valuable research work in this widely accepted, user friendly journal. I hope my collaboration with JCDR will continue for a long time".



Dr. Arundhathi. S
MBBS, MD (Pathology),
Sanjay Gandhi institute of trauma and orthopedics,
Bengaluru.
On Aug 2018




Dr. Mamta Gupta,
"It gives me great pleasure to be associated with JCDR, since last 2-3 years. Since then I have authored, co-authored and reviewed about 25 articles in JCDR. I thank JCDR for giving me an opportunity to improve my own skills as an author and a reviewer.
It 's a multispecialty journal, publishing high quality articles. It gives a platform to the authors to publish their research work which can be available for everyone across the globe to read. The best thing about JCDR is that the full articles of all medical specialties are available as pdf/html for reading free of cost or without institutional subscription, which is not there for other journals. For those who have problem in writing manuscript or do statistical work, JCDR comes for their rescue.
The journal has a monthly publication and the articles are published quite fast. In time compared to other journals. The on-line first publication is also a great advantage and facility to review one's own articles before going to print. The response to any query and permission if required, is quite fast; this is quite commendable. I have a very good experience about seeking quick permission for quoting a photograph (Fig.) from a JCDR article for my chapter authored in an E book. I never thought it would be so easy. No hassles.
Reviewing articles is no less a pain staking process and requires in depth perception, knowledge about the topic for review. It requires time and concentration, yet I enjoy doing it. The JCDR website especially for the reviewers is quite user friendly. My suggestions for improving the journal is, more strict review process, so that only high quality articles are published. I find a a good number of articles in Obst. Gynae, hence, a new journal for this specialty titled JCDR-OG can be started. May be a bimonthly or quarterly publication to begin with. Only selected articles should find a place in it.
An yearly reward for the best article authored can also incentivize the authors. Though the process of finding the best article will be not be very easy. I do not know how reviewing process can be improved. If an article is being reviewed by two reviewers, then opinion of one can be communicated to the other or the final opinion of the editor can be communicated to the reviewer if requested for. This will help one’s reviewing skills.
My best wishes to Dr. Hemant Jain and all the editorial staff of JCDR for their untiring efforts to bring out this journal. I strongly recommend medical fraternity to publish their valuable research work in this esteemed journal, JCDR".



Dr. Mamta Gupta
Consultant
(Ex HOD Obs &Gynae, Hindu Rao Hospital and associated NDMC Medical College, Delhi)
Aug 2018




Dr. Rajendra Kumar Ghritlaharey

"I wish to thank Dr. Hemant Jain, Editor-in-Chief Journal of Clinical and Diagnostic Research (JCDR), for asking me to write up few words.
Writing is the representation of language in a textual medium i e; into the words and sentences on paper. Quality medical manuscript writing in particular, demands not only a high-quality research, but also requires accurate and concise communication of findings and conclusions, with adherence to particular journal guidelines. In medical field whether working in teaching, private, or in corporate institution, everyone wants to excel in his / her own field and get recognised by making manuscripts publication.


Authors are the souls of any journal, and deserve much respect. To publish a journal manuscripts are needed from authors. Authors have a great responsibility for producing facts of their work in terms of number and results truthfully and an individual honesty is expected from authors in this regards. Both ways its true "No authors-No manuscripts-No journals" and "No journals–No manuscripts–No authors". Reviewing a manuscript is also a very responsible and important task of any peer-reviewed journal and to be taken seriously. It needs knowledge on the subject, sincerity, honesty and determination. Although the process of reviewing a manuscript is a time consuming task butit is expected to give one's best remarks within the time frame of the journal.
Salient features of the JCDR: It is a biomedical, multidisciplinary (including all medical and dental specialities), e-journal, with wide scope and extensive author support. At the same time, a free text of manuscript is available in HTML and PDF format. There is fast growing authorship and readership with JCDR as this can be judged by the number of articles published in it i e; in Feb 2007 of its first issue, it contained 5 articles only, and now in its recent volume published in April 2011, it contained 67 manuscripts. This e-journal is fulfilling the commitments and objectives sincerely, (as stated by Editor-in-chief in his preface to first edition) i e; to encourage physicians through the internet, especially from the developing countries who witness a spectrum of disease and acquire a wealth of knowledge to publish their experiences to benefit the medical community in patients care. I also feel that many of us have work of substance, newer ideas, adequate clinical materials but poor in medical writing and hesitation to submit the work and need help. JCDR provides authors help in this regards.
Timely publication of journal: Publication of manuscripts and bringing out the issue in time is one of the positive aspects of JCDR and is possible with strong support team in terms of peer reviewers, proof reading, language check, computer operators, etc. This is one of the great reasons for authors to submit their work with JCDR. Another best part of JCDR is "Online first Publications" facilities available for the authors. This facility not only provides the prompt publications of the manuscripts but at the same time also early availability of the manuscripts for the readers.
Indexation and online availability: Indexation transforms the journal in some sense from its local ownership to the worldwide professional community and to the public.JCDR is indexed with Embase & EMbiology, Google Scholar, Index Copernicus, Chemical Abstracts Service, Journal seek Database, Indian Science Abstracts, to name few of them. Manuscriptspublished in JCDR are available on major search engines ie; google, yahoo, msn.
In the era of fast growing newer technologies, and in computer and internet friendly environment the manuscripts preparation, submission, review, revision, etc and all can be done and checked with a click from all corer of the world, at any time. Of course there is always a scope for improvement in every field and none is perfect. To progress, one needs to identify the areas of one's weakness and to strengthen them.
It is well said that "happy beginning is half done" and it fits perfectly with JCDR. It has grown considerably and I feel it has already grown up from its infancy to adolescence, achieving the status of standard online e-journal form Indian continent since its inception in Feb 2007. This had been made possible due to the efforts and the hard work put in it. The way the JCDR is improving with every new volume, with good quality original manuscripts, makes it a quality journal for readers. I must thank and congratulate Dr Hemant Jain, Editor-in-Chief JCDR and his team for their sincere efforts, dedication, and determination for making JCDR a fast growing journal.
Every one of us: authors, reviewers, editors, and publisher are responsible for enhancing the stature of the journal. I wish for a great success for JCDR."



Thanking you
With sincere regards
Dr. Rajendra Kumar Ghritlaharey, M.S., M. Ch., FAIS
Associate Professor,
Department of Paediatric Surgery, Gandhi Medical College & Associated
Kamla Nehru & Hamidia Hospitals Bhopal, Madhya Pradesh 462 001 (India)
E-mail: drrajendrak1@rediffmail.com
On May 11,2011




Dr. Shankar P.R.

"On looking back through my Gmail archives after being requested by the journal to write a short editorial about my experiences of publishing with the Journal of Clinical and Diagnostic Research (JCDR), I came across an e-mail from Dr. Hemant Jain, Editor, in March 2007, which introduced the new electronic journal. The main features of the journal which were outlined in the e-mail were extensive author support, cash rewards, the peer review process, and other salient features of the journal.
Over a span of over four years, we (I and my colleagues) have published around 25 articles in the journal. In this editorial, I plan to briefly discuss my experiences of publishing with JCDR and the strengths of the journal and to finally address the areas for improvement.
My experiences of publishing with JCDR: Overall, my experiences of publishing withJCDR have been positive. The best point about the journal is that it responds to queries from the author. This may seem to be simple and not too much to ask for, but unfortunately, many journals in the subcontinent and from many developing countries do not respond or they respond with a long delay to the queries from the authors 1. The reasons could be many, including lack of optimal secretarial and other support. Another problem with many journals is the slowness of the review process. Editorial processing and peer review can take anywhere between a year to two years with some journals. Also, some journals do not keep the contributors informed about the progress of the review process. Due to the long review process, the articles can lose their relevance and topicality. A major benefit with JCDR is the timeliness and promptness of its response. In Dr Jain's e-mail which was sent to me in 2007, before the introduction of the Pre-publishing system, he had stated that he had received my submission and that he would get back to me within seven days and he did!
Most of the manuscripts are published within 3 to 4 months of their submission if they are found to be suitable after the review process. JCDR is published bimonthly and the accepted articles were usually published in the next issue. Recently, due to the increased volume of the submissions, the review process has become slower and it ?? Section can take from 4 to 6 months for the articles to be reviewed. The journal has an extensive author support system and it has recently introduced a paid expedited review process. The journal also mentions the average time for processing the manuscript under different submission systems - regular submission and expedited review.
Strengths of the journal: The journal has an online first facility in which the accepted manuscripts may be published on the website before being included in a regular issue of the journal. This cuts down the time between their acceptance and the publication. The journal is indexed in many databases, though not in PubMed. The editorial board should now take steps to index the journal in PubMed. The journal has a system of notifying readers through e-mail when a new issue is released. Also, the articles are available in both the HTML and the PDF formats. I especially like the new and colorful page format of the journal. Also, the access statistics of the articles are available. The prepublication and the manuscript tracking system are also helpful for the authors.
Areas for improvement: In certain cases, I felt that the peer review process of the manuscripts was not up to international standards and that it should be strengthened. Also, the number of manuscripts in an issue is high and it may be difficult for readers to go through all of them. The journal can consider tightening of the peer review process and increasing the quality standards for the acceptance of the manuscripts. I faced occasional problems with the online manuscript submission (Pre-publishing) system, which have to be addressed.
Overall, the publishing process with JCDR has been smooth, quick and relatively hassle free and I can recommend other authors to consider the journal as an outlet for their work."



Dr. P. Ravi Shankar
KIST Medical College, P.O. Box 14142, Kathmandu, Nepal.
E-mail: ravi.dr.shankar@gmail.com
On April 2011
Anuradha

Dear team JCDR, I would like to thank you for the very professional and polite service provided by everyone at JCDR. While i have been in the field of writing and editing for sometime, this has been my first attempt in publishing a scientific paper.Thank you for hand-holding me through the process.


Dr. Anuradha
E-mail: anuradha2nittur@gmail.com
On Jan 2020

Important Notice

Reviews
Year : 2023 | Month : April | Volume : 17 | Issue : 4 | Page : DE11 - DE14 Full Version

Exploring the Profile of the Gut Microbiome in Differentiating Type 2 Diabetes Mellitus and Non Alcoholic Fatty Liver Disease


Published: April 1, 2023 | DOI: https://doi.org/10.7860/JCDR/2023/60968.17763
Yashasvi Anand, Shiv Joshi

1. Undergraduate, Jawaharlal Nehru Medical College, Wardha, Maharashtra, India. 2. Faculty, Department of Community Medicine, Jawaharlal Nehru Medical College, Wardha, Maharashtra, India.

Correspondence Address :
Yashasvi Anand,
Undergraduate, Jawaharlal Nehru Medical College, Sawangi, Wardha-442005, Maharashtra, India.
E-mail: anandyashasvi555@gmail.com

Abstract

Type 2 Diabetes Mellitus (T2DM) and Non Alcoholic Fatty Liver Disease (NAFLD) are emerging global pandemics and carry a significant burden of co-morbidity and mortality. Asian Indians have the highest prevalence of T2DM, leading to 2.54 million deaths yearly. In India, it is 11.6%, and 30-50% of patients with NAFLD have diabetes. Patients with worsening T2DM tend to have increased progression of NAFLD to cirrhosis. NAFLD leads to end-stage liver disease causing 2.59 million deaths annually. Therefore, the relationship between T2DM and NAFLD needs to be disclosed, and the gut microbiome shows significant characteristics for the same. The gut microbiome is a collection of trillions of bacteria, archaea and fungi that resides in the digestive tract of humans. It plays a significant role in health by helping control digestion and benefits for human body immune system. Progression of metabolic health disorders shows changes in the quality and heterogeneity of the gut microbiome. It has been established that metabolic and immunological disorders are mainly influenced by the gut microbiome and not by the type of diet. Butyrate-producing bacteria benefit insulin resistance leading to more chances of T2DM. Since, the liver is close to the gut microbiome, the influence of the gut microbiome and its metabolites affecting liver function is great. But, gut microbiome being specific in both cases can assist in exploring the relationship and differentiating one from the other. Therefore, further analysis and studies are required to understand the role of the gut microbiome and its significance in better diagnosis.

Keywords

Archaea and fungi, Bacteria, Diabetes, Dysbiosis, Gut flora, Gut-liver axis, Obesity

The Type 2 diabetes mellitus (T2DM) and non alcoholic fatty liver disease are emerging as a global pandemic and carry a significant burden of comorbidity and mortality. The worldwide prevalence of T2DM is 1 out of 10 people. In India, prevalence of Non Alcoholic Fatty Liver Disease (NAFLD) is 11.6% and 30-50% of patients with NAFLD are diabetic. Asian Indians have the highest prevalence of T2DM leading to 2.54 million deaths every year. NAFLD leads to end-stage liver disease causing 2.59 million deaths annually (1). The prevalence of NAFLD is 59.67% in T2DM (2). Patients with worsening T2DM tend to have increased progression of NAFLD to cirrhosis. Heart disease in NAFLD increases 1.87 times in cases with T2DM. Since, the liver is in a close affinity with the gut microbiome, the influence of the gut microbiome and its metabolites affecting liver function is high (3). The gut microbiome is a collection of trillions of bacteria, archaea and fungi that resides in the digestive tract of humans. It plays a significant role in health by helping control digestion and is beneficial to human immune system. Progression of metabolic health disorders shows changes in the quality and heterogeneity of the gut microbiome. It has been established that metabolic and immunological disorders are mainly influenced by the gut microbiome and not by the type of diet. Butyrate-producing bacteria benefits insulin resistance leading to more chances of T2DM (4). But, gut microbiome being specific in both cases can assist in exploring the relationship or differentiating one from the other. Thereby, this review aims to further analyse and understand the role of gut microbiome and its relationship between T2DM and NAFLD for better diagnosis.

PRESENTATION OF T2DM AND NAFLD

The human gastrointestinal tract is an important site for organism residing in mutualism. According to the recent data trillions of organisms are found in human gut (5). There, presence is highly fluctuating depending on different factors responsible for the aetiology and development of diseases [6,7]. The recent studies have exposed vital role of gut microbiome as an important factor responsible for metabolic comorbidities such as diabetes, obesity, cardiovascular diseases, and NAFLD (8),(9),(10),(11),(12),(13),(14),(15),(16),(17). The ongoing pandemic obesity is creating a havoc worldwide causing huge number of T2DM cases. Obesity is a risk factor leading to metabolic disorder, since its causes increased insulin resistance, hypertension, etc., (18),(19). Exploring gut microbiome is essential as said by Hippocrates-‘All diseases begins in the gut’. According to the recent studies in 55% cases of T2DM, showed presence of NAFLD and other way round (1),(20),(21). In addition, its association has a poorer prognosis and high mortality rate (22). Ongoing research has revealed that changes in gut microbiome are characteristic features of these two metabolic diseases (23),(24). In this review article, we explored the profile of gut microbiome in differentiating T2DM and NAFLD on the basis of specific microbiome presence.

GUT MICROBIOME AND ITS SIGNIFICANCE

Gut microbiome is a collection of trillions of bacteria, archaea and fungi that resides in mutualism in the digestive tract of human. It has an important role in human health by controlling digestion and is also beneficial for human immune system. As a metabolic disorder develops in human body, it shows changes in the diversity of gut microbe. The essential fuel for this gut microbiome is probiotics, it helps the gut microbe to become strong and healthy. This fact has been proven by necessary intake of probiotic supplement for middle aged or old age people as their gut flora becomes weak with increased age. It has also proven to be effective during stress thus preventing from stress related comorbidities. When a pathogen enters in human body, through contaminated food or water pathogen fights with microbe present in gut for nutrient and space, thus gut microbes weaken the pathogen. Also, when toxic food consumes, gut microbe breaks it into amino acid and vitamin which can serve as an essential biomarker. Since, immune system is challenged regularly by favourable organism through pathogens and gut microbe evolved mutually so intelligently that, they play a major role in immunological well-being (12). Growth of microbes starts soon after the birth of baby depending on factors like: type of delivery feeding pattern, then it remains constant till adulthood (25),(26),(27),(28),(29). When person changes diet, use of medication, diabetic drug and proton pump inhibitor causes change in gut flora (30),(31),(32),(33). Obesity is referred to as intake of excessive calories then burned by normal daily activity (34). These imbalance is recognised by hypothalamus in brain which causes behavioural and metabolic responses in order to balance the variation [35,36]. This two-way connection of central nervous system with enteric nervous system and its regulation is called as gut-brain axis. This accounts for its creditability with all other organs, such as brain and endocrine organ and its metabolites and hormones acts as key messenger (37).

Gut Microbiome in NAFLD

The major cause of metabolic disorder is linked to obese individual. An essential role is played by the gut flora in causing metabolic disorders related to obese individual, this is done by production of Short Chain Fatty Acids (SCFA) that induces energy scavenging [38-40]. The microbes present in gut induces the absorption of simple carbohydrates like glucose, fructose and galactose from intestine, leading to the production of fatty acids from acetyl-CoA through this carbohydrate metabolism causing accumulation of triglycerides in adipocytes. Insulin resistance fastens adipocyte cumulation and leads to inflammation in liver (41). This increases with time causing the development of NAFLD. These deleterious bacteria are transported into circulation but a natural barrier that is our gut epithelium prevents its translocation.

The gut-liver axis is defined as a two-way correlation with gut, and its microbiome and liver. On the contrary, dysbiosis is defined as imbalance in the gut microbial number that is associated with disease. This leads to gut barrier damage causing translocation of metabolites from gut wall to portal vein. This causes release of bile acids and Farnesoid X Receptor (FXR) causing lipotoxicity that leads to mitochondrial dysfunction causing lipid accumulation in hepatocytes that is development of NAFLD. On the other hand, dysbiosis also causes release of Lipopolysaccharides (LPS), pathogen associated molecular pattern that acts on Kupffer cells causing inflammation in liver that further progression of NAFLD. This upsurge of LPS level in circulation is referred to as “metabolic endotexemia” generally observed in metabolic diseases (42). This LPS integrates with LPS binding protein and next to it themenocyte differentiate antigen (CD-14)-TLR-4-complex mediating inflammatory reaction and insulin and activates inflammation (43).

Broad range of physiological activity produces bile acids from cholesterol. This bile acids help in digestion, absorption of fat containing foods and conserves the gut membrane putting a stop to metabolic translocation [44,45]. In cases of NAFLD, the disparity in the gut microbial association is primarily explained by age. It has been hypothesised that the presence of Megamonas and Ruminococcus is seen in case of NAFLD only (24). Enterobacter and Clostridium has shown to associated with NAFLD [46,47]. While Romboutsia over existed in slim patients of NAFLD (48). Influence of medication on gut microbiome has been comprehensively observed. NAFLD deals with need of specified medical treatment by means of drugs that is distinct pharmacotherapy. It indicates change in the ongoing sedentary lifestyle in addition to alteration in diet pattern is beholden as far as finest treatment strategy for control and prevention of further development of the disease.

Gut Microbiome in T2DM and its Effect on Cardio Metabolism

Dietary regimen is a regulator of the make-up and the ramification of the gut microbiome (49). Clinical trials have disclosed few characteristic feature in which dietary regimen can make alteration 12to the gut microbiome (50). Initially, the microbiome makes changes instantly, when disclosed to substantial and quick variation in feeding pattern. Military diet that is short-term diet variation that includes chop and changes in between vegetarian diet and non vegetarian diet or including an additional 40 gm fibre per day to the dietary regimen. Subsequently a diet with varying fat containing food or fibre driven food can alter human gut microbiome in the ramification and make-up of the gut microbiome that is noteworthy in 48 hours [50,51]. High-fibre diet has revealed to ameliorate insulin resistance in slim and in overweight subject with T2DM. And important point to note here is that only regular, constant, long-term, dietary regimen are significant to all intent and purposed in stating the health of the gut microbe ramification. Military dietary regimen ceases to function the alteration of the major makeup and categorisation of the gut flora. It is believed that metabolites that are developed from the gut flora in response to metabolisation of diet consumed are key factors impacting human biology, contrarily the effect to nutrients are impacted by microbe present in gut. Two such micronutrients that influence the gut flora are Choline and Trimethyl Amine N-Oxide (TMAO). It has been studied that inadequate choline intake in human regulates the gut flora with varied levels of Gammaproteobacteria and Erysipelotrichia and this are in a straight line associated with NAFLD progression (52). In some studies, on animal models it has been observed that obesity is directly associated with gut microbiome (53). This is demonstrated in a study on genetically obese mice which has half and half cut back of Bacteroidetes and rise of Firmicutes in contrast to their slim brothers and sisters (53). This variation influences consumption level of microbes and these obese mice shows expanded function in deriving nutrition from digested food.

Gut Microbe Derived Short Chain Fatty Acids (SCFA)

The main source of energy for human beings is derived from the food intake. This food intake in regular terms is referred to as dietary regimen. When food enters into human body it is broken down into small molecule by the gut microbes. These molecules are then absorbed through different mechanism. These have a direct effect on various cells of human organ like hepatocytes through the absorption of metabolites by the portal vein. In the liver these metabolites run away from the first pass metabolism and enters into the circulation leading to various consequences on human biology (54). In a balance diet human body receives varied substrate like carbohydrates, lipids, amino acids and iron which are broken down in the lumen of the small intestine, where the gut microbes convert it into specific metabolites. Few carbohydrates are indigestible and therefore they are roasted by the gut microbiome leading to formation of SCFA, in which the most essential ones are acetate, butyrate, lactate and propionate (55). Now the response of human body on these metabolites are reciprocated on the basis of synthesis of SCFA and relative liver clearance, leading to the production of fatty acids from acetyl-CoA (acetyl coenzyme A) during carbohydrate metabolism and subsequent other procedure goes hand in hand, while a small amount enters into the circulation (53). It is of key importance here that all the SCFA does not have similar effect. This effect of gut microbiota in the synthesis of SCFA has been shown using oral antibiotic treatment that causes extreme outcome on the synthesis of maximum number of metabolites (56).

In this article, the profile of gut microbiome was reviewed in case of T2DM and NAFLD. The gut microbiome has a different profile in terms of taxon found in T2DM and NAFLD. Specific taxon for NAFLD was recognised that is Ruminococcus and Megamonas (24). While Enterobacter, Romboutsia, and Clostridium linked to both NAFLD and T2DM these were also linked to diabetes marker like Hb1Ac and fasting blood glucose as shown in (Table/Fig 1) (46),(47),(48).

Conclusion

To conclude, helped us by identifying the gut microbiome establish relationship with host parameters that are specific for diabetes mellitus and liver disease; and a further approach to analyse and validate the results by cohort study. The recent studies have exposed vital role of gut microbiome as an important factor responsible for metabolic comorbidities. The reliability of gut-brain axis on all the other organs plays a vital role as a messenger. Further research that aims at enhancing the detection, cure and therapeutic treatment of these metabolic disorders is required to establish the role of using the gut microbiome for diagnostic purposes. Also, primary research needs to be done in order to further analyse these gut microbiomes in anticipation of the advancement and evolving nature of this metabolic disorder.

References

1.
Younossi ZM, Golabi P, de Avila L, Paik JM, Srishord M, Fukui N, et al. The global epidemiology of NAFLD and NASH in patients with type 2 diabetes: A systematic review and meta-analysis. J Hepatol. 2019;71(4):793801. [crossref][PubMed]
2.
Atan NAD, Koushki M, Motedayen M, Dousti M, Sayehmiri F, Vafaee R, et al. Type 2 diabetes mellitus and non-alcoholic fatty liver disease: A systematic review and meta-analysis. Gastroenterol Hepatol Bed Bench. 2017;10(Suppl1):S01-07.
3.
Tsai HJ, Tsai YC, Hung WW, Hung WC, Chang CC, Dai CY. Gut microbiota and non-alcoholic fatty liver disease severity in type 2 diabetes patients. JPM. 2021;11(3):238. [crossref][PubMed]
4.
Chen Z, Radjabzadeh D, Chen L, Kurilshikov A, Kavousi M, Ahmadizar F, et al. Association of Insulin resistance and type 2 diabetes with gut microbial diversity: A microbiome-wide analysis from population studies. JAMA Netw Open. 2021;4(7):e2118811. [crossref][PubMed]
5.
Minemura M, Shimizu Y. Gut microbiota and liver diseases. World J Gastroenterol. 2015;21(6):1691-702. [crossref][PubMed]
6.
Hooper LV, Wong MH, Thelin A, Hansson L, Falk PG, Gordon JI. Molecular analysis of commensal host-microbial relationships in the intestine. Science. 2001;291(5505):881-84. [crossref][PubMed]
7.
de La Serre CB, Ellis CL, Lee J, Hartman AL, Rutledge JC, Raybould HE. Propensity to high-fat diet-induced obesity in rats is associated with changes in the gut microbiota and gut inflammation. Am J Physiol Gastrointest Liver Physiol. 2010;299(2):G440-48. [crossref][PubMed]
8.
Qin J, Li Y, Cai Z, Li S, Zhu J, Zhang F, et al. A metagenome-wide association study of gut microbiota in type 2 diabetes. Nature. 2012;490(7418):55-60. [crossref][PubMed]
9.
Delzenne NM, Cani PD, Everard A, Neyrinck AM, Bindels LB. Gut microorganisms as promising targets for the management of type 2 diabetes. Diabetologia. 2015;58(10):2206-17. [crossref][PubMed]
10.
Escobedo G, López-Ortiz E, Torres-Castro I. Gut microbiota as a key player in triggering obesity, systemic inflammation and insulin resistance. Rev Invest Clin. 2014;66(5):450-59.
11.
Mehal WZ. The Gordian knot of dysbiosis, obesity and NAFLD. Nat Rev Gastroenterol Hepatol. 2013;10(11):637-44. [crossref][PubMed]
12.
Henao-Mejia J, Elinav E, Jin C, Hao L, Mehal WZ, Strowig T, et al. Inflammasome-mediated dysbiosis regulates progression of NAFLD and obesity. Nature. 2012;482(7384):179-85. [crossref][PubMed]
13.
DiBaise JK, Zhang H, Crowell MD, Krajmalnik-Brown R, Decker GA, Rittmann BE. Gut microbiota and its possible relationship with obesity. Mayo Clin Proc. 2008;83(4):460-69. [crossref][PubMed]
14.
Chong-Nguyen C, Duboc H, Sokol H. The gut microbiota, a new cardiovascular risk factor? Presse Med. 2017;46(7-8 Pt 1):708-13. [crossref][PubMed]
15.
Kitai T, Tang WHW. The role and impact of gut microbiota in cardiovascular disease. Rev Esp Cardiol (Engl Ed). 2017;70(10):799-800. [crossref][PubMed]
16.
Tang WHW, Kitai T, Hazen SL. Gut microbiota in cardiovascular health and disease. Circ Res. 2017;120(7):1183-96. [crossref][PubMed]
17.
Wieland A, Frank DN, Harnke B, Bambha K. Systematic review: Microbial dysbiosis and nonalcoholic fatty liver disease. Aliment Pharmacol Ther. 2015;42(9):1051-63.[crossref][PubMed]
18.
Semenkovich CF. Insulin resistance and atherosclerosis. J Clin Invest. 2006;116(7):1813-22. [crossref][PubMed]
19.
Hotamisligil GS. Inflammation and metabolic disorders. Nature. 2006;444(7121):860-67. [crossref][PubMed]
20.
Adams LA, Waters OR, Knuiman MW, Elliott RR, Olynyk JK. NAFLD as a risk factor for the development of diabetes and the metabolic syndrome: An eleven-year follow-up study. Am J Gastroenterol. 2009;104(4):861-67. [crossref][PubMed]
21.
Zelber-Sagi S, Lotan R, Shibolet O, Webb M, Buch A, Nitzan-Kaluski D, et al. Non-alcoholic fatty liver disease independently predicts prediabetes during a 7-year prospective follow-up. Liver Int. 2013;33(9):1406-12. [crossref][PubMed]
22.
Ferguson D, Finck BN. Emerging therapeutic approaches for the treatment of NAFLD and type 2 diabetes mellitus. Nat Rev Endocrinol. 2021;17(8):484-95. [crossref][PubMed]
23.
Loomba R, Seguritan V, Li W, Long T, Klitgord N, Bhatt A, et al. Gut microbiome-based metagenomic signature for non-invasive detection of advanced fibrosis in human nonalcoholic fatty liver disease. Cell Metab. 2017;25(5):1054-62.e5. [crossref][PubMed]
24.
Lee G, You HJ, Bajaj JS, Joo SK, Yu J, Park S, et al. Distinct signatures of gut microbiome and metabolites associated with significant fibrosis in non-obese NAFLD. Nat Commun. 2020;11(1):4982. [crossref][PubMed]
25.
Biasucci G, Rubini M, Riboni S, Morelli L, Bessi E, Retetangos C. Mode of delivery affects the bacterial community in the newborn gut. Early Hum Dev. 2010;86 Suppl 1:13-15. [crossref][PubMed]
26.
Jakobsson HE, Abrahamsson TR, Jenmalm MC, Harris K, Quince C, Jernberg C, et al. Decreased gut microbiota diversity, delayed Bacteroidetes colonisation and reduced Th1 responses in infants delivered by caesarean section. Gut. 2014;63(4):559-66. [crossref][PubMed]
27.
Bokulich NA, Chung J, Battaglia T, Henderson N, Jay M, Li H, et al. Antibiotics, birth mode, and diet shape microbiome maturation during early life. Sci Transl Med. 2016;8(343):343ra82. [crossref][PubMed]
28.
Faith JJ, Guruge JL, Charbonneau M, Subramanian S, Seedorf H, Goodman AL, et al. The long-term stability of the human gut microbiota. Science. 2013;341(6141):1237439. [crossref][PubMed]
29.
Schloissnig S, Arumugam M, Sunagawa S, Mitreva M, Tap J, Zhu A, et al. Genomic variation landscape of the human gut microbiome. Nature. 2013;493(7430):45-50. [crossref][PubMed]
30.
Falony G, Joossens M, Vieira-Silva S, Wang J, Darzi Y, Faust K, et al. Population-level analysis of gut microbiome variation. Science. 2016;352(6285):560-64. [crossref][PubMed]
31.
Forslund K, Hildebrand F, Nielsen T, Falony G, Le Chatelier E, Sunagawa S, et al. Disentangling type 2 diabetes and metformin treatment signatures in the human gut microbiota. Nature. 2015;528(7581):262-66. [crossref][PubMed]
32.
Wu H, Esteve E, Tremaroli V, Khan MT, Caesar R, Mannerås-Holm L, et al. Metformin alters the gut microbiome of individuals with treatment-naive type 2 diabetes, contributing to the therapeutic effects of the drug. Nat Med. 2017;23(7):850-58. [crossref][PubMed]
33.
Freedberg DE, Toussaint NC, Chen SP, Ratner AJ, Whittier S, Wang TC, et al. Proton pump inhibitors alter specific taxa in the human gastrointestinal microbiome: A crossover trial. Gastroenterology. 2015;149(4):883-85.e9. [crossref][PubMed]
34.
Schoeller DA. Insights into energy balance from doubly labeled water. Int J Obes (Lond). 2008;32 Suppl 7:S72-75. [crossref][PubMed]
35.
Ahima RS, Antwi DA. Brain regulation of appetite and satiety. Endocrinol Metab Clin North Am. 2008;37(4):811-23. [crossref][PubMed]
36.
Apovian CM, Garvey WT, Ryan DH. Challenging obesity: Patient, provider, and expert perspectives on the roles of available and emerging nonsurgical therapies. Obesity (Silver Spring). 2015;23 Suppl 2:S1-26. [crossref][PubMed]
37.
Li Z, Yi CX, Katiraei S, Kooijman S, Zhou E, Chung CK, et al. Butyrate reduces appetite and activates brown adipose tissue via the gut-brain neural circuit. Gut. 2018;67(7):1269-79. [crossref][PubMed]
38.
Ley RE, Turnbaugh PJ, Klein S, Gordon JI. Microbial ecology: Human gut microbes associated with obesity. Nature. 2006;444(7122):1022-23. [crossref][PubMed]
39.
Samuel BS, Shaito A, Motoike T, Rey FE, Backhed F, Manchester JK, et al. Effects of the gut microbiota on host adiposity are modulated by the short-chain fatty-acid binding G protein-coupled receptor, Gpr41. Proc Natl Acad Sci USA. 2008;105(43):16767-72. [crossref][PubMed]
40.
Wong JMW, de Souza R, Kendall CWC, Emam A, Jenkins DJA. Colonic health: Fermentation and short chain fatty acids. J Clin Gastroenterol. 2006;40(3):235-43. [crossref][PubMed]
41.
Farrell GC. Signalling links in the liver: Knitting SOCS with fat and inflammation. J Hepatol. 2005;43(1):193-96. [crossref][PubMed]
42.
Cani PD, Amar J, Iglesias MA, Poggi M, Knauf C, Bastelica D, et al. Metabolic endotoxemia initiates obesity and insulin resistance. Diabetes. 2007;56(7):1761-72. [crossref][PubMed]
43.
Schoeler M, Caesar R. Dietary lipids, gut microbiota and lipid metabolism. Rev Endocr Metab Disord. 2019;20(4):461-72. [crossref][PubMed]
44.
Lorenzo-Zúñiga V, Bartolí R, Planas R, Hofmann AF, Viñado B, Hagey LR, et al. Oral bile acids reduce bacterial overgrowth, bacterial translocation, and endotoxemia in cirrhotic rats. Hepatology. 2003;37(3):551-57. [crossref][PubMed]
45.
Ogata Y, Nishi M, Nakayama H, Kuwahara T, Ohnishi Y, Tashiro S. Role of bile in intestinal barrier function and its inhibitory effect on bacterial translocation in obstructive jaundice in rats. J Surg Res. 2003;115(1):18-23. [crossref][PubMed]
46.
Oh TG, Kim SM, Caussy C, Fu T, Guo J, Bassirian S, et al. A universal gut-microbiome-derived signature predicts cirrhosis. Cell Metab. 2020;32(5):878-88.e6. [crossref][PubMed]
47.
Wang B, Jiang X, Cao M, Ge J, Bao Q, Tang L, et al. Altered fecal microbiota correlates with liver biochemistry in nonobese patients with non-alcoholic fatty liver disease. Sci Rep. 2016;6(1):32002. [crossref][PubMed]
48.
Chen F, Esmaili S, Rogers GB, Bugianesi E, Petta S, Marchesini G, et al. Lean NAFLD: A distinct entity shaped by differential metabolic adaptation. Hepatology. 2020;71(4):1213-27. [crossref][PubMed]
49.
Sonnenburg JL, Bäckhed F. Diet-microbiota interactions as moderators of human metabolism. Nature. 2016;535(7610):56-64.[crossref][PubMed]
50.
Wu GD, Chen J, Hoffmann C, Bittinger K, Chen YY, Keilbaugh SA, et al. Linking long-term dietary patterns with gut microbial enterotypes. Science. 2011;334(6052):105-08. [crossref][PubMed]
52.
Wu GD, Compher C, Chen EZ, Smith SA, Shah RD, Bittinger K, et al. Comparative metabolomics in vegans and omnivores reveal constraints on diet-dependent gut microbiota metabolite production. Gut. 2016;65(1):63-72. [crossref][PubMed]
52.
Spencer MD, Hamp TJ, Reid RW, Fischer LM, Zeisel SH, Fodor AA. Association between composition of the human gastrointestinal microbiome and development of fatty liver with choline deficiency. Gastroenterology. 2011;140(3):976-86. [crossref][PubMed]
53.
Bäckhed F, Ding H, Wang T, Hooper LV, Koh GY, Nagy A, et al. The gut microbiota as an environmental factor that regulates fat storage. Proc Natl Acad Sci USA. 2004;101(44):15718-23. [crossref][PubMed]
54.
Holmes E, Li JV, Marchesi JR, Nicholson JK. Gut microbiota composition and activity in relation to host metabolic phenotype and disease risk. Cell Metab. 2012;16(5):559-64. [crossref][PubMed]
55.
Roy CC, Kien CL, Bouthillier L, Levy E. Short-chain fatty acids: Ready for prime time? Nutr Clin Pract. 2006;21(4):351-66. [crossref][PubMed]
56.
Cho I, Yamanishi S, Cox L, Methé BA, Zavadil J, Li K, et al. Antibiotics in early life alter the murine colonic microbiome and adiposity. Nature. 2012;488(7413):621-26.[crossref][PubMed]

Tables and Figures
[Table / Fig - 1]
DOI and Others

DOI: 10.7860/JCDR/2023/60968.17763

Date of Submission: Oct 22, 2022
Date of Peer Review: Nov 17, 2022
Date of Acceptance: Dec 24, 2022
Date of Publishing: Apr 01, 2023

AUTHOR DECLARATION:
• Financial or Other Competing Interests: None
• Was Ethics Committee Approval obtained for this study? NA
• Was informed consent obtained from the subjects involved in the study? NA
• For any images presented appropriate consent has been obtained from the subjects. NA

PLAGIARISM CHECKING METHODS:
• Plagiarism X-checker: Oct 29, 2022
• Manual Googling: Nov 28, 2022
• iThenticate Software: Dec 12, 2022 (12%)

ETYMOLOGY: Author Origin

JCDR is now Monthly and more widely Indexed .
  • Emerging Sources Citation Index (Web of Science, thomsonreuters)
  • Index Copernicus ICV 2017: 134.54
  • Academic Search Complete Database
  • Directory of Open Access Journals (DOAJ)
  • Embase
  • EBSCOhost
  • Google Scholar
  • HINARI Access to Research in Health Programme
  • Indian Science Abstracts (ISA)
  • Journal seek Database
  • Google
  • Popline (reproductive health literature)
  • www.omnimedicalsearch.com